Legis Daily

A bill to allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.

USA115th CongressS-1049| Senate 
| Updated: 5/4/2017
Margaret Wood Hassan

Margaret Wood Hassan

Democratic Senator

New Hampshire

Cosponsors (1)
Todd Young (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Opioid Addiction Risk Transparency Act This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 4, 2017
Introduced in Senate
May 4, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 4, 2017
    Introduced in Senate


  • May 4, 2017
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Related Bills

  • S 115-934: FDA Reauthorization Act of 2017
Drug safety, medical device, and laboratory regulationDrug therapyHealth personnel

A bill to allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.

USA115th CongressS-1049| Senate 
| Updated: 5/4/2017
Opioid Addiction Risk Transparency Act This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 4, 2017
Introduced in Senate
May 4, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 4, 2017
    Introduced in Senate


  • May 4, 2017
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Margaret Wood Hassan

Margaret Wood Hassan

Democratic Senator

New Hampshire

Cosponsors (1)
Todd Young (Republican)

Health, Education, Labor, and Pensions Committee

Health

Related Bills

  • S 115-934: FDA Reauthorization Act of 2017
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Drug safety, medical device, and laboratory regulationDrug therapyHealth personnel